Boehringer Ingelheim and Circuit Therapeutics have entered into a research collaboration for the discovery of new ways of treating psychiatric disorders. Circuit Therapeutics’ flagship technology, optogenetics platform allows the identification and characterization of drug targets from brain circuits involved in normal and pathological behaviors and allows the control of individual nerve cells and circuits. The companies will combine R&D capabilities to provide novel avenues for drug discove...